Scientific article

Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function

Published inInternational Journal of Cardiology, vol. 231, p. 1-5
Publication date2017

Among endocannabinoid (EC)-related mediators, Oleoyl-ethanolamide (OEA) and Palmitoyl-ethanolamide (PEA), two endogenous PPARα agonists with lipolytic and anti-inflammatory action, respectively, are being actively investigated. Here, we assessed the potential association between plasma levels of PEA and OEA and coronary function in a cohort including normal, overweight, obese, and morbidly obese (MOB) individuals.

  • Biomarkers/blood
  • Body Mass Index
  • Chromatography, Liquid
  • Coronary Artery Disease/blood/diagnosis/etiology
  • Coronary Circulation/physiology
  • Coronary Vessels/diagnostic imaging/physiopathology
  • Electrocardiography
  • Enzyme-Linked Immunosorbent Assay
  • Ethanolamines/blood
  • Humans
  • Obesity/blood/complications
  • Palmitic Acids/blood
  • Positron Emission Tomography Computed Tomography
  • Regional Blood Flow/physiology
  • Vasoconstriction/physiology
Citation (ISO format)
QUERCIOLI, Alessandra et al. Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. In: International Journal of Cardiology, 2017, vol. 231, p. 1–5. doi: 10.1016/j.ijcard.2016.12.023
Main files (1)
Article (Published version)
ISSN of the journal0167-5273

Technical informations

Creation09/19/2018 9:41:00 AM
First validation09/19/2018 9:41:00 AM
Update time03/15/2023 3:12:50 PM
Status update03/15/2023 3:12:50 PM
Last indexation10/19/2023 9:39:12 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack